Institutional members access full text with Ovid®

Share this article on:

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; Zovato, Stefania; Donach, Martin; Nicoletto, Ornella; Farina, Miriam; Furini, Lara; Ceravolo, Renato; Carli, Paolo; Lombardi, Giuseppe

doi: 10.1097/CAD.0b013e3283340d1f
Case Reports

In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizumab are reserved for first-line treatment, but despite various guidelines, optimal treatment is still uncertain. We present, for the first time, a case of a good response to second-line bevacizumab and interferon-α in a patient who failed classical sunitinib treatment.

Oncologia Medica, Istituto Oncologico Veneto – IRCCS, Padova, Italy

Correspondence to Dr Giuseppe Lombardi, MD, Istituto Oncologico Veneto-IRCSS, via Gattamelata, 64, 35128-Padova, Italy

Tel: +39 340 0593278; fax: +39 049 8215904;


Received 27 August 2009 Revised form accepted 9 October 2009

© 2010 Lippincott Williams & Wilkins, Inc.